Company Encyclopedia
View More
name
Insulet
PODD.US
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.
1.407 T
PODD.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking13/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.68%A
    • Profit Margin9.76%B
    • Gross Margin72.22%A
  • Growth ScoreB
    • Revenue YoY27.11%A
    • Net Profit YoY-41.51%D
    • Total Assets YoY0.13%C
    • Net Assets YoY23.80%A
  • Cash ScoreB
    • Cash Flow Margin1024.29%B
    • OCF YoY27.11%A
  • Operating ScoreB
    • Turnover0.83B
  • Debt ScoreC
    • Gearing Ratio54.31%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Insulet Wins FDA Clearance for Enhanced Omnipod 5 Algorithm

    Insulet Corporation has received FDA clearance for enhancements to its Omnipod 5 Automated Insulin Delivery System, including a lower glucose target and improved automated experience. These updates aim to simplify insulin delivery and improve outcomes for diabetes patients, launching in the US in early 2026.

    Reuters·
    US
    PODD
    +2.72%
    Reuters·
    US
    PODD
    +2.72%

    Insulet (PODD): Assessing Valuation After Recent Share Price Cooldown

    Insulet (PODD) shares have cooled recently despite a solid year-to-date performance. The stock is currently undervalued by 18.7%, with a fair value of $378.21. Analysts project a 17.8% annual revenue growth and an increase in profit margins to 14.1% over the next three years. However, high P/E ratios and competition in diabetes devices pose risks. Investors should consider these factors when evaluating Insulet's potential as a long-term investment.

    Simplywall·
    US
    PODD
    +2.72%
    Simplywall·
    US
    PODD
    +2.72%

    Insulet Corp. stock outperforms competitors on strong trading day

    Insulet Corp. (PODD) stock rose 1.83% to $155.19 on Friday, outperforming its competitors and the broader market. Despite this daily gain, the stock remains significantly below its 52-week high of $367.65. This performance comes as the S&P 500

    MSN·
    US
    PODD
    +2.72%
    MSN·
    US
    PODD
    +2.72%

    Rhenman & Partners Asset Management AB Has $14.45 Million Stock Holdings in Insulet Corporation $PODD

    Rhenman & Partners Asset Management AB reduced its stake in Insulet Corporation by 24.6% in Q2, owning 46,000 shares worth $14.45 million. Insulet is the fund's 21st largest holding, comprising 1.8% of its portfolio. Other investors like American Century Companies and Vanguard Group have increased their holdings. Insulet's stock performance is strong, with a market cap of $23.13 billion and recent earnings surpassing expectations.

    Market Beat·
    US
    PODD
    +2.72%
    Market Beat·
    US
    PODD
    +2.72%

    Shareholder Manea Files To Sell 4,475 Of Insulet Corp [PODD]

    Shareholder Manea Dan of Insulet Corp (PODD) filed a Form 144 with the SEC on November 26, 2025, to sell 4,475 restricted shares through Fidelity Brokerage Services. The sale must occur within 90 days of filing.

    Reuters·
    US
    PODD
    +2.72%
    Reuters·
    US
    PODD
    +2.72%
    © 2025 Longbridge｜Disclaimer